CXCL12 and breast cancer: In Lewis lung carcinoma model (LLC1s) and mouse models of breast cancer metastasis (MMTV-PyMT), treatment with cyclophosphamide, paclitaxel and doxorubicin significantly increase CD206+ TAMs accumulation arround CXCL12-rich tumor cells, suggested that tumor-mediated CXCL12 recruits CD206+ TAMs resulting in chemoresistance (Hughes et al., 2015).